Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The AFORRD trial is asking three important questions:
What proportion of people with Type 2 Diabetes are likely to be treated satisfactorily with a
fixed dose of a statin that lowers blood cholesterol levels to help reduce the risk of heart
disease? To what extent do omega-3 fatty acids lower blood triglyceride levels when given
with or without a statin? Are there simple techniques that can help people to take their
tablets on a regular basis?
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.